Week 1, December 2025: Antibody Therapeutics in Psoriasis: Mechanisms and Milestones

Psoriasis affects more than 100 million people around the world. The field of monoclonal antibody (mAb) therapeutics has evolved from broad immunosuppressants to engineered biologics targeting key cytokine nodes in psoriatic inflammation, namely TNF-α, IL-17, and IL-23. This trend has been driven by improved understanding of cytokine networks, increasing emphasis on deep lesion clearance, and patient-centered metrics such as quality of life and treatment durability. Just last week, China gave the approval of picankibart (PECONDLE®), a novel IL-23p19-targeting mAb! 

Cytokines and IL-23p19

Antibodies targeting the IL-23p19 subunit have emerged as a preferred class for psoriasis due to their high specificity, efficacy, and safety profile. Molecules such as guselkumab, risankizumab, and tildrakizumab have demonstrated superior or comparable outcomes to IL-17 inhibitors, with longer remission intervals and fewer adverse events. IL-23 functions upstream in the Th17 axis, driving IL-17 production and sustaining keratinocyte activation. The clinical rationale for p19-selective inhibition lies in its ability to suppress pathogenic inflammation without disrupting IL-12-dependent protective immunity.

Picankibart Drug Approval

On November 28, picankibart (PECONDLE®) was approved by the NMPA. Developed by Innovent Biologics, this IL-23p19 monoclonal antibody demonstrated >80% PASI 90 response at week 16 in the CLEAR-1 Phase 3 trial, with durable efficacy and a 12-week maintenance dosing schedule, which is the longest among IL-23 biologics currently available. As the first domestically produced biologic in this class approved in China, picankibart signals regional biopharmaceutical maturity and is expected to improve access and compliance due to its extended dosing interval and local availability. 

The Window of Opportunity

Emerging data suggest that early initiation of biologic therapy may induce prolonged remission, even after treatment cessation. Trials such as STEPIn and GUIDE show that patients treated within one year of disease onset exhibit delayed or absent relapse post-discontinuation, with immunologic and epigenetic correlates supporting a disease-modifying effect. The presence of skin-resident TRM cells and innate immune memory in keratinocytes are thought to underlie relapse risk. These insights have shifted focus toward early aggressive intervention and personalized de-escalation strategies. 

Immunogenicity and Anti-Drug Antibodies (ADA)

A persistent challenge in biologic therapy is the development of anti-drug antibodies (ADA), which can neutralize therapeutic efficacy or increase clearance. ADA incidence varies across agents: risankizumab and tildrakizumab show ADA rates up to 31% and 18%, respectively, though often without clinical impact. Drug design (e.g., humanization, Fc engineering), concomitant immunosuppressive use, and dosing strategies are all being optimized to mitigate ADA-related loss of response. 

Future Outlook: Toward Remission

With multiple IL-23p19 inhibitors now clinically validated and picankibart joining the portfolio, the therapeutic goal in psoriasis is transitioning from symptomatic control to durable remission. Incorporation of immune monitoring, epigenetic biomarkers, and treatment sequencing strategies will be critical in guiding decisions on initiation, maintenance, and potential withdrawal.